Achieve Life Sciences (ACHV) Stock Analysis

What Achieve Life Sciences does

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Key metrics

ETFs linked to ACHV

Broad-market and Healthcare sector ETFs an investor holding Achieve Life Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ACHV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Achieve Life Sciences?

Achieve Life Sciences trades under the ticker ACHV on NASDAQ.

Which exchange is ACHV listed on?

ACHV is listed on NASDAQ.

What sector does Achieve Life Sciences operate in?

Achieve Life Sciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ACHV in a portfolio?

PortView shows ACHV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.